Background and aims: The prevalence of diabetes mellitus is becoming an epidemic. The diversity of etiological factors contributes to the fact that both types of diabetes mellitus occur among different age groups and among different segments of the population. Activation of various types of processes that lead to oxidative stress, endothelial dysfunction, the development of atherosclerotic changes, increases the risk of macro-and microvascular complications in diabetes mellitus. Material and methods: The experiments were performed on 172 white Wistar rats weighing 120-150 g. All animals were kept on a standard I. Horbachevsky Ternopil National Medical University (TNMU), vivarium diet. In our studies, for the first time was established a distinct cardioprotective effect of quercetin-containing drugs, Corvitin and Lipoflavon, for the purpose of normalizing disorders in type 1 and type 2 diabetes mellitus coupled with obesity, which opens wide opportunities for the introduction of these drugs into diabetic cardiomyopathy. Results: The results obtained are an experimental rationale for extending the indications of clinical use of Corvitin and Lipoflavon. Conclusion: Lipoflavon in the experimental type 1 and type 2 diabetes mellitus coupled with obesity significantly outperforms Corvitin in terms of TBA-active products and diene conjugates. key words: antioxydants, obesity, hard disease, metabolic syndrome
stroke [3] . In Ukraine, the main place in the mortality structure of patients with diabetes are occupying by myocardial infarction (55 %) and stroke (29 %), which is 70 times higher than the mortality rate from microvascular complications and diabetic coma (1-4 %) [4] . Diabetic cardiomyopathy is one of the leading forms of cardiac damage in diabetes, the main pathogenetic factor of which considering to be metabolic and structural disorders in the heart muscle, including through the discoordination of redox processes, the development of tissue hypoxia and to the activation of oxidative stress.
Given the high medical and social importance, one of the leading tasks of modern diabetes is to find new effective methods of correction diabetic heart disease. To prevent damage caused by oxidative stress, the use of drugs with antioxidant activity are warranting in diabetes treatment [5] . Quercetin is one of the modern remedies that have proven to be highly effective in a variety of pathological processes, including cardiovascular disease. The original domestic preparations of this flavonoid -watersoluble (Corvitin) and liposomal (Lipoflavon)have been studied quite deeply in this research [6, 7] . They have therapeutic effect in ischemic heart disease, including acute myocardial infarction, hypertension, and chronic heart failure [8] . Cardioprotective activity of quercetin-containing drugs are providing by their antioxidant, membrane-protective, angioprotective, neuro-and endocrine-modulating action, and ability to increase adaptation to hypoxia and stimulate synthesis of nitric oxide in the tissue of the heart [9] .
However, information on the use and therapeutic activity of quercetin-containing drugs in cardiomyopathy, which develops in diabetes of various types, is limited. Therefore, it is promising to study the comparative effectiveness of water-soluble and liposomal drugs based on this flavonoid in heart damage, which develops in experimental type 1 and type 2 diabetes mellitus (DM) coupled with obesity, and their effects on metabolic disorders, including carbohydrate and lipid metabolism, in this pathology.
Materials and Methods
The experiments were performed on 172 white Wistar rats weighing 120-150 g. All animals were kept on a standard I. Horbachevsky Ternopil National Medical University (TNMU), vivarium diet. The studies were carried out in accordance with national and international recommendations for the protection of animals used for experimental and other scientific purposes (Strasbourg, 1986; Law of Ukraine № 3447-IV, 2006) and in accordance with the requirements of the Bioethics Commission of TNMU (Protocol, No. 29 of May 20, 2015).
All experimental animals were divided into groups: 1 and 5 -control; 2 and 6 are animals with diabetes; 3 and 7 -animals with diabetes receiving a water-soluble form of quercetin -"Corvitin" (BHFZ, Ukraine); 4 and 8 -animals with diabetes receiving liposomal preparation of quercetin -"Lipoflavon" (Biolik, PAT, Ukraine).
To simulate diabetes of both types, streptozotocin (STZ, "Sigma-Aldrich", USA) was used, which was dissolved ex tempore and injected intraperitoneally on citrate buffer (pH 4.5). Type 1 DM in animals 2, 3 and 4 groups were caused by a single injection of STZ (50 mg/kg mass) [9] . To model type 2 DM coupled with obesity, which was caused by a 4-week high-energy diet [10] in 6, 7 and 8 groups of animals was conducted by a single STZ (30 mg/kg mass) injection [11] . An appropriate amount of citrate buffer (pH 4.5) was injected to the control animal groups. The administration of Corvitin and Lipoflavon to rats of 3 and 4 groups (with type 1 DM) was started 2 weeks after STZ injection, animals of 7 and 8 groups (with type 2 DM) 10 weeks after STZ injection. Watersoluble and liposomal drugs were used at doses of 100 and 370 mg/kg, respectively (10 mg/kg in terms of quercetin), intraperitoneally, daily and for 14 days.
The development of diabetes confirmed by determining blood glucose and glycosylated hemoglobin (HbA1C) which presented in previous studies [12] . Also, serum determined concentration of TBA-active products (TBA) and catalase (Cat). In the heart was analyzed the activity of lipid peroxidation (LPO), lipid hydro peroxides (LНPО), TBA-active products and diene conjugates (DC), antioxidant system -by the activity of superoxide dismutase (SOD) catalase and the content of reduced glutathione (RG). The activity of succinate dehydrogenase (SDG) and cytochrome oxidase (CChO) were determined for the analysis of oxidative processes in the mitochondria of the heart. The total lipid composition of the blood was determined by the content of total cholesterol (CTC) (using the Liquck Cor-CHOL set, Cormay, Poland), triglycerides (TG) (using the Liquck Cor-CHOL set, Cormay, Poland), lowdensity lipoproteins (LDL) (using HC-LDL DIRECT kit, Cormay, Poland) and high-density lipoproteins (HDL) (using HC-LDL DIRECT kit, Cormay, Poland). The determination of leptin level (by standard DRG Leptin reagent kit, Sandwich ELISA, Germany) in the blood.
Statistical processing of the results was performed using IBM SPSS Statistiса v.10.1 programs and Microsoft Excel ХР. The obtained values by using the Student's t-test were compared and the non-parametric Mann-Whitney U-test. The difference between the studied parameters was considered statistically significant at p≤0.05.
Results
Our previous studies found significant changes in carbohydrate metabolism that indicated the development of diabetes [12] .
Effect of Corvitin and Lipoflavon on blood biochemical parameters and morphofunctional status of the heart in type 1 diabetes mellitus.
In type 1 diabetes mellitus, the problems with lipid metabolism is also noted: TC, TG, LDL in serum increased by 44, 54 and 249 % respectively HDL, on the contrary, decreased by 64 % (the significance of the difference with the control group of animals was in all cases p<0.001) ( Fig. 1 ). Figure 1 . Indicators of lipid metabolism in the serum of animals with type 1 diabetes mellitus and Corvitin and Lipoflavon administration. Notes: * -is significant in comparison with the markers of control animals; # -is significant between the type 1 DM; ** -is significant between the groups of type 1 DM + Corvitin.
In myocardium at type 1 DM significantly increased the content of products of peroxide degradation of lipid components of cardiomyocyte membranes LНPО -by 33%, TBA-active products -by 169%, DC -by 147 %. At the same time, there was an increase in the activity of Cat and SOD, but a decrease in the content of RG by 24 % (Table 1) . <0,05* Notes: 1. p -is significant in comparison with the markers of control animals; р 1 -is significant between the type 1 DM; р 2 -is significant between the groups of type 1 DM + Corvitin.
In type 1 DM, there was a decrease in the activity of the heart tissue of SDG and CChO (by 20 and 15 %, respectively).
In groups of animals with diabetes, where for correction was used quercetin-containing drugs, observed positive changes in lipid metabolism (see Fig. 1 The investigational drugs at type 1 DM significantly reduced the manifestations of oxidative stress in the heart tissue (Table 1) 
Effect of Corvitin and Lipoflavon on biochemical parameters in the blood and morpho-functional status of the heart in type 2 diabetes mellitus coupled with obesity
Along with the increase of glucose levels and glycosylated hemoglobin [12] marked increase in serum adipocyte hormonelipocytokine leptin by 139 %, compared with the control group of animals. (Table 2 ).
In animals with type 2 diabetes coupled with obesity, in the myocardium was detected an increase of products of peroxide degradation of the lipid components of the cardiomyocyte membranes: LHPO -by 26 %, TBA-active products -by 96 %, DC -by 116 % (Table 3) .
At the same time, changes in the antioxidant system were observed in the heart: an increase SOD and catalase activity (by 46 and 32%), and a decrease the content of RG (by 21%) (Table 3 ). In the myocardium was reduced the activity of mitochondrial SDG and CChO.
There was a significant decrease in the concentration of leptin when administered Corvitin by 34%, Lipoflavon -by 42 %. Moreover, the activity of Lipoflavon significantly exceeded the activity of Corvitin, by influencing the content of leptin by 12 % ( Table 2) .
The use of Corvitin-containing drugs showed a significant decrease in myocardial content of GPL, TBA-active products and DCby 19, 42 and 49 %, with the introduction of Lipoflavon -by 24, 52 and 54 %, respectively, both drugs contributed to the normalization of these indicators (Table 3) .
With the introduction of Corvitin and Lipoflavon, the activity of Cat in the myocardium significantly decreased by 12 % and 14 % and did not differ from the level of control. Corvitin and Lipoflavon contributed to an increase in myocardial RG content of 14 and 20 %, respectively. In addition, Lipoflavon normalized the activity of SOD (Table 3) . <0,001* <0,001* p 2 <0,001* Notes: 1. p -is significant in comparison with the markers of control animals; р 1 -is significant between the type 2 DM; р 2 -is significant between the groups of type 2 DM + Corvitin. <0,01* <0,001* p 2 >0,05 Notes: 1. p -is significant in comparison with the markers of control animals; р 1 -is significant between the type 2 DM; р 2 -is significant between the groups of type 2 DM + Corvitin
Discussion
Thus, Corvitin and Lipoflavon exhibit cardioprotective activity in type 1 and type 2 diabetes mellitus coupled with obesity. Both drugs, to a greater extent Lipoflavon, effectively suppress free-radical oxidation, normalize antioxidant status, reduces disorders of carbohydrate and lipid metabolism. In type 2 DM, it reduces leptin content.
Proving the effectiveness of Corvitin and Lipoflavon conteining drugs at cardiomyopathy, which develops in experimental diabetes mellitus, substantiates the feasibility of further in-depth study of their properties with the prospect of successful use as cardioprotective agents in this pathology.
Conclusions
Corvitin and, to a greater extent, Lipoflavon in type 1 diabetes mellitus contribute to a significant decrease in the blood content of total cholesterol, triglycerides, low-density lipoproteins with a simultaneous increase in the amount of high-density lipoproteins and decrease the level of TBA-active products. In the tissue of the heart -a significant decrease in the number of lipid hydroperoxides, diene conjugates, TBA-active products, restoration of the activity and content of components of the antioxidant system, improvement of the functional state of mitochondria, the level of synthesis of nitric oxide, against the background of endogenous intoxication.
Corvitin and, largely, Lipoflavon in type 2 DM coupled with obesity contribute to a significant decrease in blood leptin levels, a decrease the content of TBA-active products and catalase activity. In myocardial tissue -decrease in the content of lipid hydroperoxides, diene conjugates, TBA-active products, catalase activity, increase in the level of reduced glutathione, activity of mitochondrial enzymes, which occurs against the background of decreasing endogenous intoxication.
Lipoflavon in the experimental type 1 and type 2 diabetes mellitus coupled with obesity significantly outperforms Corvitin in terms of TBA-active products and diene conjugates.
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